Elizabeth R Plimack

Elizabeth R Plimack

UNVERIFIED PROFILE

Are you Elizabeth R Plimack?   Register this Author

Register author
Elizabeth R Plimack

Elizabeth R Plimack

Publications by authors named "Elizabeth R Plimack"

Are you Elizabeth R Plimack?   Register this Author

100Publications

3728Reads

40Profile Views

Clinical implications of molecular subtyping in bladder cancer.

Curr Opin Urol 2019 Jul;29(4):350-356

Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000641DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681908PMC
July 2019

Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies.

Eur Urol Oncol 2019 Jul 31;2(4):355-364. Epub 2019 Jan 31.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.01.002DOI Listing
July 2019

First-line Immunotherapy in Metastatic Urothelial Carcinoma.

Eur Urol Focus 2019 May 15. Epub 2019 May 15.

Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.04.015DOI Listing
May 2019

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 03 16;380(12):1116-1127. Epub 2019 Feb 16.

From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) - all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient Clinic (D.N.), and Hertzen Moscow Cancer Research Institute (B.A.), Moscow; the Christie NHS Foundation Trust, Manchester (R.H.), and Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, and Queen Mary University of London, London (T.P.) - all in the United Kingdom; Centre Hospitalier Universitaire (CHU) de Québec and Université Laval, Quebec, QC (F.P.), and CHU de Montréal, Montreal (D.S.) - both in Canada; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (S.J.A.); Centre Antoine Lacassagne, Université Côte d'Azur, Nice (D.B.), and Hôpitaux Universitaires de Lyon, Lyon (S. Tartas) - both in France; Military Institute of Medicine, Warsaw, Poland (C.S.); Rocky Mountain Cancer Center, Colorado Springs, CO (M.M.); Adelaide and Meath Hospital and University College Dublin, Dublin (R.S.M.); the Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany (J.B.); Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Osaka City University Hospital, Osaka, Japan (S. Tamada); MSD China, Beijing (Q.S.); Merck, Kenilworth, NJ (R.F.P., M.C.); and Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816714DOI Listing
March 2019

Update on perioperative systemic therapy for urothelial carcinoma.

Clin Adv Hematol Oncol 2019 Mar;17(3):176-183

Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
March 2019

Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.

Curr Urol Rep 2018 Nov 7;19(12):109. Epub 2018 Nov 7.

Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111-2497, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11934-018-0851-7
Publisher Site
http://dx.doi.org/10.1007/s11934-018-0851-7DOI Listing
November 2018

Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma.

Clin Adv Hematol Oncol 2018 Oct;16(10):677-686

Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
October 2018

Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.

Eur Urol 2018 09 5;74(3):387-393. Epub 2018 Jun 5.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.05.025DOI Listing
September 2018

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Eur Urol Oncol 2018 08 30;1(3):190-198. Epub 2018 May 30.

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.05.002DOI Listing
August 2018

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

J Clin Oncol 2018 06 11;36(16):1588-1593. Epub 2018 Apr 11.

Eric Jonasch, Rebecca S. Slack, Summer Stovall, Donna Juarez, Troy R. Gilchrist, Lisa Pruitt, and Nizar M. Tannir, The University of Texas MD Anderson Cancer Center; Elshad Hasanov, The University of Texas Health Science Center, Houston, TX; Daniel M. Geynisman and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; W. Kimryn Rathmell, Vanderbilt Ingram Cancer Center, Nashville, TN; and Moshe C. Ornstein and Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.1485
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.1485DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804828PMC
June 2018

Chemoimmunotherapy in Metastatic Urothelial Carcinoma.

Eur Urol 2018 05 10;73(5):760-762. Epub 2018 Jan 10.

Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.12.029DOI Listing
May 2018

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

J Clin Oncol 2018 04 31;36(11):1080-1087. Epub 2018 Jan 31.

Christos E. Kyriakopoulos, Glenn Liu, and David F. Jarrard, University of Wisconsin (UW) School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI; Yu-Hui Chen and Christopher J. Sweeney, Dana-Farber Cancer Institute; Yu-Hui Chen, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group; Christopher J. Sweeney, Harvard Medical School, Boston, MA; Michael A. Carducci, Noah M. Hahn, and Mario Eisenberger, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Daniel H. Shevrin, NorthShore University HealthSystem, Evanston; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Matthew M. Cooney, Seidman Cancer Center, University Hospitals Cleveland Medical Center; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891129PMC
April 2018

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

J Clin Oncol 2018 04 9;36(11):1088-1095. Epub 2018 Mar 9.

Alicia K. Morgans, Maha Hussain, and David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Yu-Hui Chen and Christopher J. Sweeney, Dana Farber Cancer Institute, Boston, MA; David F. Jarrard, University of Wisconsin Hospital and Clinics, Madison, WI; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Elizabeth R. Plimack and Benjamin A. Gartrell, Montefiore Medical Center, Bronx, NY; Michael A. Carducci, Johns Hopkins University, Baltimore, MD; Jorge A. Garcia, Cleveland Clinic, Cleveland, OH; Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY; and Linda J. Patrick-Miller, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891128PMC
April 2018

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 Apr 21;378(14):1277-1290. Epub 2018 Mar 21.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile; Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France; Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London; Aarhus University Hospital, Aarhus, Denmark (F.D.); Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.); British Columbia Cancer Agency, Vancouver, Canada (C.K.K.); Westmead Hospital and Macquarie University, Sydney (H.G.); Jena University Hospital, Jena, Germany (M.-O.G.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.); Niigata University, Niigata, Japan (Y.T.); Hospital Universitario 12 de Octubre, Madrid (D.C.); Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.); and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1712126
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1712126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549PMC
April 2018

Provider and patient burdens of obtaining oral anticancer medications.

Am J Manag Care 2018 04 1;24(4):e128-e133. Epub 2018 Apr 1.

Fox Chase Cancer Center, Temple University Health System, 333 Cottman Ave, Philadelphia, PA 19111. Email:

View Article

Download full-text PDF

Source
April 2018

Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake.

Immunotherapy 2018 03;10(6):423-425

Hematology/Oncology, Fox Chase Cancer Center, Temple Health, 333 Cottman Ave, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0007DOI Listing
March 2018

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

J Clin Oncol 2018 02 20;36(4):376-382. Epub 2017 Dec 20.

Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.3921
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.3921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805480PMC
February 2018

Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer.

Bladder Cancer 2018 Jan 20;4(1):9-18. Epub 2018 Jan 20.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-170129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798524PMC
January 2018

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

J Clin Oncol 2017 Dec 5;35(34):3851-3858. Epub 2017 Jul 5.

Hans J. Hammers, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; David F. McDermott, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Lionel D. Lewis, The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH; Martin H. Voss, Memorial Sloan Kettering Cancer Center, New York, NY; Padmanee Sharma, MD Anderson Cancer Center, University of Texas, Houston, TX; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Albiruni R. Abdul Razak, Princess Margaret Cancer Centre, Toronto, Ontario; Christian Kollmannsberger, British Columbia Cancer Agency, Vancouver, British Columbia; Daniel Y.C. Heng, Tom Baker Cancer Center, University of Calgary, Calgary; Jennifer Spratlin, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; M. Brent McHenry, Bristol-Myers Squibb, Princeton, NJ; and Asim Amin, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.72.1985
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.72.1985DOI Listing
December 2017

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis.

J Natl Compr Canc Netw 2017 10;15(10):1224-1233

From Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2017.0161DOI Listing
October 2017

Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.

J Natl Compr Canc Netw 2017 06;15(6):841-847

From Department of Hematology/Oncology, Fox Chase Cancer Center, and Temple Health, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2017.0103DOI Listing
June 2017

Bending the Curve of Advanced Urothelial Carcinoma.

J Oncol Pract 2017 05;13(5):319-320

Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.023325DOI Listing
May 2017

Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.

Curr Treat Options Oncol 2017 01;18(1)

Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, 333 Cottman Avenue, Philadelphia, PA, 19111-2497, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-017-0458-0DOI Listing
January 2017

Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?

Eur Urol 2016 12 26;70(6):971-973. Epub 2016 May 26.

Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.05.026DOI Listing
December 2016

Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.

Urol Oncol 2016 12;34(12):538-547

Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.10.017DOI Listing
December 2016

Circulating biomarkers to guide systemic therapy for urothelial carcinoma.

Urol Oncol 2016 11 15;34(11):502-509. Epub 2016 Oct 15.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.08.019DOI Listing
November 2016

Systemic therapy for bladder cancer finally comes into a new age.

Future Oncol 2016 Oct 12;12(19):2227-42. Epub 2016 Jul 12.

Fox Chase Cancer Center, Temple Health. 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066115PMC
October 2016

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

J Natl Compr Canc Netw 2016 10;14(10):1213-1224

From Vanderbilt-Ingram Cancer Center; Moffitt Cancer Center; Huntsman Cancer Institute at the University of Utah; Patient Advocate; Mayo Clinic Cancer Center; Stanford Cancer Institute; Massachusetts General Hospital Cancer Center; University of Colorado Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Fox Chase Cancer Center; Roswell Park Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Memorial Sloan Kettering Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fred & Pamela Buffett Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Michigan Comprehensive Cancer Center; City of Hope Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Yale Cancer Center/Smilow Cancer Hospital; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Washington/Seattle Cancer Care Alliance; The University of Texas MD Anderson Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379654PMC
http://dx.doi.org/10.6004/jnccn.2016.0131DOI Listing
October 2016

National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.

J Clin Oncol 2016 09 25;34(27):3346-8. Epub 2016 Jul 25.

Sumanta Kumar Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Neeraj Agarwal, Huntsman Cancer Institute, Salt Lake City, UT; Stephen Anthony Boorjian, Mayo Clinic, Rochester, MN; Noah M. Hahn, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Arlene O. Siefker-Radtke, Vanderbilt University, Nashville, TN; Peter E. Clark, MD Anderson Cancer Center, Houston, TX; and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379635PMC
September 2016

Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress.

J Clin Oncol 2016 06 9;34(18):2088-92. Epub 2016 May 9.

Fox Chase Cancer Center, Temple Health, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1420DOI Listing
June 2016

Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions.

Immunotherapy 2016 06;8(7):785-98

Department of Medical Oncology, Fox Chase Cancer Center, Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2016-0028DOI Listing
June 2016

Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care.

Future Oncol 2016 Apr 17;12(7):887-91. Epub 2016 Feb 17.

Fox Chase Cancer Center - Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0023DOI Listing
April 2016

Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma.

Cancer Med 2016 Feb 18;5(2):192-9. Epub 2015 Dec 18.

Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.577DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735777PMC
February 2016

Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm.

Oncology (Williston Park) 2016 Feb;30(2):160-2, 176

View Article

Download full-text PDF

Source
February 2016

Targeting Signaling Transduction Pathways in Bladder Cancer.

Curr Oncol Rep 2015 Dec;17(12):58

Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-015-0477-6DOI Listing
December 2015

Measuring the Efficacy and Value of Urothelial Cancer Urinary Biomarkers.

Ann Intern Med 2015 Dec 27;163(12):954-5. Epub 2015 Oct 27.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/M15-2445DOI Listing
December 2015

Muscle-invasive urothelial bladder cancer: an update on systemic therapy.

Ther Adv Urol 2015 Dec;7(6):312-30

Assistant Professor of Medical Oncology, Fox Chase Cancer Center-Temple University Health System, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756287215607418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647143PMC
December 2015

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1803-13. Epub 2015 Sep 25.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; Institut Gustave Roussy, Villejuif (B.E.), and Bordeaux University Hospital, Hôpital Saint André, Bordeaux (A.R.) - both in France; Beth Israel Deaconess Medical Center (D.F.M.) and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.) - all in Boston; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.); Stanford Cancer Institute, Stanford, CA (S.S.); University of Washington and Fred Hutchinson Cancer Research Center, Seattle (S.S.T.); Vanderbilt University Medical Center, Nashville (J.A.S.); Fondazione Istituto Nazionale Tumori, Milan (G.P.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hospital Universitario 12 De Octubre, Madrid (D.C.); Westmead Hospital and Macquarie University, Sydney (H.G.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Helsinki University Central Hospital and University of Helsinki, Helsinki (P.B.); South West Wales Cancer Institute and Swansea University College of Medicine, Swansea (J.W.), and Royal Marsden Hospital, London (J.L.) - both in the United Kingdom; University Hospital Essen of University of Duisburg-Essen, Germany (T.C.G.); Chiba Cancer Center, Chiba (T.U.), and Niigata University, Niigata (Y.T.) - both in Japan; Hospital Sao Jose, Beneficencia Portuguesa de São Paulo, São Paulo (F.A.S.); British Columbia Cancer Agency, Vancouver, BC, Canada (C.K.); Bristol-Myers Squibb, Lawrenceville (J.S.S., I.M.W.) and Hopewell (L.-A.X.) - both in New Jersey; and M.D. Anderson Cancer Center, University of Texas, Houston (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719487PMC
November 2015

Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?

Eur Urol 2015 Oct 23;68(4):578-80. Epub 2015 Jun 23.

Medical Oncology, Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.06.009DOI Listing
October 2015

Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach.

J Natl Compr Canc Netw 2015 Jun;13(6):811-22

From Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts; Division of Medical Oncology, Moffitt Cancer Center, Tampa, Florida; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Division of Medical Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Division of Oncology, Stanford University Medical Center, Palo Alto, California; Division of Hematology/Oncology, The University of California, San Francisco, California; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0094DOI Listing
June 2015

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

J Clin Oncol 2015 May 1;33(13):1430-7. Epub 2014 Dec 1.

Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York; Saby George, Roswell Park Cancer Institute, Buffalo, NY; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; David F. McDermott, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Bruce G. Redman, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ulka N. Vaishampayan, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Timothy M. Kuzel, Northwestern University Feinberg School of Medicine, Chicago, IL; Michael R. Harrison, Duke University Medical Center, Durham, NC; Harry A. Drabkin, Medical University of South Carolina, Charleston, SC; Theodore F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Kim A. Margolin, Stanford University, Stanford, CA; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Alexandre M. Lambert, Bristol-Myers Squibb, Braine-l'Alleud, Belgium; Ian M. Waxman, Bristol-Myers Squibb, Princeton, NJ; and Hans J. Hammers, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0703DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806782PMC
May 2015

A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite.

Clin Genitourin Cancer 2015 Apr 28;13(2):142-9. Epub 2014 Sep 28.

Department of Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.08.005DOI Listing
April 2015

Kidney cancer, version 3.2015.

J Natl Compr Canc Netw 2015 Feb;13(2):151-9

From Memorial Sloan Kettering Cancer Center; The University of Texas MD Anderson Cancer Center; Huntsman Cancer Institute at the University of Utah; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Colorado Cancer Center; City of Hope Comprehensive Cancer Center; Roswell Park Cancer Institute;University of Washington/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0022DOI Listing
February 2015

Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.

J Clin Oncol 2014 Dec 10;32(36):4171-2. Epub 2014 Nov 10.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.5281DOI Listing
December 2014

Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.

Discov Med 2014 Dec;18(101):341-50

Department of Hematology/Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
December 2014